Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Today's Featured Story
AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?Authored by Thomas Hughes. Posted: 4/29/2026. 
Key Points
- AbbVie is amid a trend-following opportunity, underpinned by cash flow and capital return.
- Institutions are accumulating aggressively, limiting downside risk in Q2.
- Analyst trends suggest a fresh all-time high is coming; the only question is how quickly the stock price will rise.
- Special Report: Elon Musk’s $1 Quadrillion AI IPO
AbbVie's (NYSE: ABBV) share price has been under pressure from rising costs and concerns about how robust its post‑Humira performance will be. The decline, however, set up a trend‑following buy signal that triggered after its Q1 earnings. The results initially left investors wanting more, but the early‑session sell‑off at the open prompted renewed buying interest. The share price moved up immediately from the session low, confirming support at a key level and suggesting a high potential for a rebound (see options activity).
When the SpaceX IPO launches, most retail investors will be locked out. The banks, funds, and insiders get in early - while everyone else waits on the sidelines.
But one small infrastructure supplier - a critical piece Musk can't scale the Colossus network without - is still trading well under institutional radar. A new briefing reveals the name and ticker at no cost. Get the SpaceX infrastructure stock name and ticker here
AbbVie’s trend‑following setup rests on its long‑term, 150‑week exponential moving average (EMA), the recent price action, and momentum indicators such as MACD and the stochastic oscillator. The 150‑week EMA has acted as a trend line for years, and current price action continues to respect it. 
The recent candlestick formed a Hammer Doji, a pattern that often signals the end of a downtrend as the market hammers out a bottom. Momentum indicators show the market is oversold and bearish pressure has been extreme, which sets the stage for a potential rebound. The trigger for that rebound could be straightforward: value and the dividend. AbbVie Presents a Value and Yield Opportunity Smart Money Is BuyingAs of late April, AbbVie trades at roughly 14x its current‑year earnings forecast — about 40% below its long‑term average — opening the door to meaningful upside. That valuation is supported by a 3.4% dividend yield at these levels, with distribution growth expected. Since the spin‑off from Abbott Laboratories (NYSE: ABT), AbbVie has increased its dividend every year. The payout ratio is on the higher side, near 65%, but that is not unusual for a high‑quality dividend payer. The critical metric is cash flow and the balance sheet, which currently support the dividend and its sustainability. On the present footing, ABBV can sustain its distributions and deliver mid‑single‑digit dividend CAGR for the foreseeable future. Analyst forecasts are consistent with this valuation. The 26 analysts tracked by MarketBeat rate the stock a Moderate Buy, with a roughly 65% buy‑side bias and nearly 30% upside to the consensus target. Activity heading into Q1 2026 included some target reductions but nothing material, as most revisions stayed within a tight range around the consensus. Analysts' sentiment appears steady, although a new catalyst from this channel may not emerge until later in the year. Institutional interest is especially notable and underpins the rebound thesis. Institutions own more than 70% of the stock and have been net buyers over the trailing 12 months. MarketBeat data show institutional buying ramped in Q1 2025, remained elevated through Q1 2026, and stayed bullish into early Q2 2026, with net purchases running at better than a $2‑to‑$1 pace during that period. Buying accelerated as the price fell, peaking at more than $4‑to‑$1, which highlights the perceived value. If institutions continue accumulating, ABBV’s bottom is likely in and a broader rebound may follow. AbbVie Puts Patent Cliff in Rear‑View MirrorAbbVie's Q1 results help address concerns about the patent cliff. Revenue rose 12.4% to $15 billion, driven by strength in Skyrizi and Rinvoq, while Humira sales declined to $668 million. The company highlighted new data showing Rinvoq outperformed Humira on the primary endpoint and met secondary objectives, supporting continued upside for Rinvoq. By segment, all but Oncology reported growth, led by a 26% increase in Neurosciences and a 16.4% gain in Immunology. Margins remain a strength. GAAP earnings missed expectations — largely due to acquired R&D milestones — but adjusted results were stronger. Adjusted EPS of $2.65 rose 7.7% year‑over‑year and missed consensus by only a slim margin. Guidance was constructive: the company raised its full‑year adjusted EPS range, bringing it more in line with market expectations. If AbbVie continues executing, including advancing its pipeline, it should be positioned to outperform in coming quarters. Key catalysts for the year include clinical trial readouts, particularly in Oncology, and label or coverage expansions for existing therapies. AbbVie has multiple applications in progress to broaden indications for blockbusters Rinvoq and Skyrizi. Risks remain — notably competition, including biosimilars for Humira — but that pressure eases over time as sales migrate to newer products. |
No comments:
Post a Comment